Monopar Therapeutics Inc.

NASDAQ:MNPR

Biotechnology

Healthcare
$70.75 +2.45%

+$1.58 today

Market cap
$479.46M
Beta
1.54
P/E (TTM)
-37.6
EPS (TTM)
-$1.76
52W Low $29.18High $105.00

Volume 0.10M

Average 0.17M

MNPR Purchases of Investments

Cash used to buy marketable securities and other investments.

Monopar Therapeutics Inc.NASDAQ: MNPR

Purchases of Investments · Q1 FY2026 · quarter ended Mar 2026

Purchases of investments growth accelerates

Q1 FY2026 purchases of investments of $40.84M (cash outflow) rose 2020.5% year over year, ahead of the +675.0% change in trailing-twelve-month purchases of investments. Sequentially, it fell 47.8% from the prior quarter. Over 3 fiscal years it compounded at +160.7% a year.

Context

  • Purchases of investments grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +2020.5% holds above the trailing-twelve-month pace of +675.0%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$40.84M-47.8% QoQ
Last fiscal yearDec 2025
-$87.15M+468.7% YoY
LTMMar 2026
-$126.06M+675.0% YoY
Purchases of Investments past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+2020.5%——
1 year+468.7%——
3-year CAGR+160.7%——
5-year CAGR——
10-year CAGR——

Purchases of Investments history

USD · from the cash flow

Latest · FY2025
(87.15M) USD
Year-over-year change
-468.7%

Purchases of Investments vs competitors

How MNPR compares with its peers on the latest reported figures

  • Peers report in different currencies, so purchases of investments is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +675.0% is the highest of 7, against a peer median of +63.9%.
  • Over three fiscal years its annual growth of +160.7% compares with a peer median of -0.9%.
MNPR Competitors
Purchases of Investments for MNPR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IMNMImmunome, Inc.LTM Sep 2026$302.18M USD+53.3%——
CMPXCompass Therapeutics, Inc.LTM Mar 2026$214.54M USD+201.7%-0.9%—
MGNXMacroGenics, Inc.LTM Mar 2026$202.4M USD+485.0%+20.0%128.9%
XNCRXencor, Inc.LTM Jun 2026$194.76M USD-62.0%-8.3%185.5%
ALXOALX Oncology Holdings Inc.LTM Mar 2026$160.3M USD+74.4%-48.5%—
MNPRMonopar Therapeutics Inc.LTM Mar 2026$126.06M USD+675.0%+160.7%—
ZYMEZymeworks Inc.LTM Sep 2026$117.65M USD-39.1%+68.9%44.2%
BCYCBicycle Therapeutics plcLTM Mar 2026$0 USD——0.0%
ADCTADC Therapeutics S.A.LTM Mar 2026$0 USD——0.0%
IPHAInnate Pharma S.A.FY2025€0 EUR——0.0%
ATNMActinium Pharmaceuticals, Inc.LTM Jun 2026$0 USD——0.0%
Peer median (excluding MNPR) —+63.9%-0.9%0.0%

Competitors are the stored peer set for MNPR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(9.1M)(10.52M)(8.4M)(15.59M)(13.72M)
Depreciation & Amortization00000
Deferred Income Tax00000
Stock-Based Compensation1.47M1.64M1.9M1.14M4.84M
Change in Working Capital317.77K1.65M(1.35M)3.49M(2.61M)
Accounts Receivables00000
Inventory00000
Accounts Payables403.97K1.48M(1.33M)506.79K388.22K
Other Working Capital(86.2K)167.52K(20.41K)2.98M(2.99M)
Other Non-Cash Items0004.55M(716.46K)
Operating Cash Flow(7.32M)(7.23M)(7.86M)(6.4M)(12.2M)
Capital Expenditures10000
Acquisitions (Net)00000
Purchases of Investments0(4.92M)(7.88M)(15.32M)(87.15M)
Sales of Investments0012.81M985.73K23.7M
Other Investing Activities00000
Investing Cash Flow0(4.92M)4.93M(14.34M)(63.45M)
Debt Repayment00000
Common Stock Issued10.93M109.34K2.07M59.4M127.71M
Common Stock Repurchased0000(35M)
Dividends Paid00000
Other Financing Activities(45.78K)(76.46K)(46.97K)(104.14K)(1.13M)
Financing Cash Flow10.88M32.87K2.03M59.29M91.57M
Effect of Forex Changes4.62K(3.48K)(16.8K)49497.27K
Net Change in Cash3.57M(12.12M)(920.11K)38.55M16.02M
Free Cash Flow(7.32M)(7.23M)(7.86M)(6.4M)(12.2M)

Monopar Therapeutics Inc.

NASDAQ:MNPR

Intrinsic Alpha fair value

Locked

Current Price

$70.75

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.